Mark Leschly
Mark Leschly
Managing Partner
“Every investment opportunity and entrepreneur is different, but our partnership approach to supporting a management team is consistent and a critical element to our success. With consistency, patience, experience, hard work and leveraging our networks and resources, our objective is to be supportive and constructive in helping entrepreneurs achieve their vision and build companies that matter.”
Mark Leschly is a Managing Partner of Rho and established Rho’s Silicon Valley office. With over 25 years of experience in technology and venture capital, Mark is an experienced and seasoned investor committed to finding and optimizing ways to support technology company CEOs and their teams to build compelling high-growth businesses.
Mark started his investment career with a focus in healthcare and broadened his investing to all of Rho’s active sectors.
Mark is a former touring professional tennis player, previously selected to the Danish Davis Cup team, and a minority owner in numerous sports teams.
Mark received an M.B.A. from Stanford University’s Graduate School of Business.
-
Charge Point
Fabletics
LiveXLive
NGM
Savage X
Tapjoy
-
Anacor (IPO; sold to Pfizer)
AqueSys (sold to Allergan)
Broadlogic (sold to Broadcom)
Dendreon (IPO)
Diversa (IPO; merged with Celunol to become Verenium)
Gloucester (acq. by Celgene)
Human Genome Sciences (IPO)
LeukoSite (acq. by Millennium Pharaceuticals)
MedImmune (IPO; acq. by AstraZeneca)
Memory (IPO)
MPV (acq. by Experian)
NitroMed (IPO)
OraMetrix (acq. by Dentsply)
PHT (sold to ERT)
Senomyx (IPO)
Tercica (IPO; acq. by Ipsen)
Vanda (IPO)
Vicuron (IPO; acq. by Pfizer)
3-D Pharmaceuticals (IPO; acq. by Johnson & Johnson)